Valued at USD 736.35 million in 2024, the neurothrombectomy devices market is projected to reach USD 784.58 million in 2025 and USD 1,418.33 million by 2034, registering a CAGR of 6.8% over the 2025–2034 forecast period. Devices in this market are used primarily in endovascular procedures performed in specialized healthcare settings such as hospitals and stroke centers. Key players include Abbott Laboratories, Johnson & Johnson Services, Inc. (Cerenovus), MicroVention, Inc., Phenox GmbH, and Vesalio, LLC.

Awareness Expands Access to Stroke Interventions

Enhanced awareness of stroke symptoms and the importance of timely medical care has led to increased utilization of neurothrombectomy devices. Initiatives that educate the public and healthcare providers about early stroke interventions have contributed to this trend. However, disparities in access to thrombectomy persist globally, with significant differences in availability between high-income and low- to middle-income countries. Addressing these gaps is crucial for equitable access to life-saving treatment.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/neurothrombectomy-devices-market

Hospitals and Ambulatory Surgical Centers

Hospitals accounted for the largest share of end-use revenue in 2024 due to their advanced diagnostic and surgical capabilities, specialized medical professionals, and state-of-the-art equipment. The ambulatory surgical centers segment is experiencing the fastest growth because of the increasing number of outpatient surgeries, shorter waiting times, and the convenience of same-day surgical care. Emergency clinics form the third end-use category in the report.

Minimally Invasive Procedures and Device Innovation

The rising demand for minimally invasive procedures and the introduction of technologically advanced products support market expansion. Next-generation stent retrievers and aspiration catheters offer improved clot retrieval efficiency and reduced procedure time. In June 2025, Terumo Neuro commercially launched the Sofia Flow 88 neurovascular aspiration catheter across EMEA markets, and in February 2025, Radical Catheter Technologies secured FDA 510(k) clearance for its 8-F neurovascular catheter. In September 2024, Vesalio launched the pVasc Thrombectomy System in the US for peripheral vascular occlusions.

Reimbursement Policies and Regional Dynamics

North America held the largest market share in 2024, driven by well-established healthcare infrastructure, high stroke prevalence, and strong reimbursement policies supporting advanced stroke treatments. Europe is expanding as well, with supportive reimbursement policies and regulators such as the European Medicines Agency and national healthcare authorities streamlining approval processes to facilitate faster adoption of neurovascular interventional devices. Increasing clinical research and collaborative initiatives between medical institutions and device manufacturers are also contributing to technological advancements in stroke treatment across the region.

Asia Pacific is expected to witness the highest CAGR during the forecast period. Countries such as China, India, and Japan are experiencing growing demand for advanced stroke treatments due to government initiatives and expanding access to neurovascular care. In October 2020, Japan announced the Japanese National Plan for Promoting Measures Against Cerebrovascular and Cardiovascular Disease. The increasing presence of international and regional medical device manufacturers, along with ongoing investments in medical research and training programs for healthcare professionals, is further accelerating adoption.

Competitive Considerations

Regulatory approvals and clinical trials play a crucial role in market penetration, and strategic collaborations, acquisitions, and partnerships are shaping the competitive environment. The growing adoption of minimally invasive neurovascular procedures, along with increasing healthcare expenditures and stroke awareness programs, is intensifying competition, and the market remains dynamic with continuous advancements aimed at enhancing patient safety and procedural success rates. High procedural costs are a restraint on the market.

Key Players in the Neurothrombectomy Devices Market

•       Abbott Laboratories

•       Acandis GmbH

•       AngioDynamics, Inc.

•       Argon Medical Devices, Inc.

•       Boston Scientific Corporation

•       Edwards Lifesciences Corporation

•       Johnson & Johnson Services, Inc. (Cerenovus)

•       LeMaitre Vascular, Inc.

•       Medtronic plc

•       MicroVention, Inc. (a subsidiary of Terumo Corporation)

•       Penumbra, Inc.

•       Phenox GmbH

•       Stryker Corporation

•       Terumo Corporation

•       Vesalio, LLC

Conclusion

Access, care setting, and policy support are shaping the direction of the neurothrombectomy devices market. As stroke awareness grows and procedures move toward outpatient and minimally invasive models, manufacturers and healthcare providers that address cost and availability gaps can capture the opportunity ahead, with the market projected to reach USD 1,418.33 million by 2034.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market